Corona Remedies IPO launched on December 8, 2025, as an Offer for Sale with a price band of ₹1,008–₹1,062. Strong grey market premium suggests high listing expectations. Subscription ends December 10, allotment on December 11, and listing on December 15, 2025. Issue size is ₹655.37 crore, entirely OFS.
Corona Remedies Limited, a Gujarat-based pharmaceutical firm, has launched its initial public offering (IPO) today, attracting significant investor attention. The issue is an Offer for Sale (OFS) by promoters and existing shareholders, aiming to raise ₹655.37 crore. The IPO price band is set between ₹1,008 and ₹1,062 per share, with subscription open from December 8 to 10, 2025. Allotment is expected by December 11, with shares set to list on the NSE and BSE on December 15, 2025.
The Corona Remedies IPO is entirely an OFS, meaning no fresh capital is being raised by the company. Retail investors can bid for a minimum of 14 shares (₹14,868 at the upper price band), while HNI and QIB categories have higher minimums. The listing date is tentatively scheduled for December 15, 2025. The grey market has shown strong interest, with the premium hovering near ₹307–₹330 per share as of early December, suggesting robust sentiment ahead of the listing.
:
Notable Updates
-
IPO opens December 8, closes December 10, 2025.
-
Price band: ₹1,008–₹1,062 per share.
-
Issue size: ₹655.37 crore (entirely OFS).
-
inimum retail investment: ₹14,868.
-
Allotment: December 11, 2025.
-
Listing: December 15, 2025 (NSE & BSE).
-
Grey Market Premium (GMP): Around ₹307–₹330, indicating strong listing expectations.
Important Points:
-
No fresh issue component; all proceeds go to selling shareholders.
-
Subscription is open for retail, HNI, and QIB investors.
-
Grey market trends signal positive sentiment for listing gains.
Sources: NDTV Profit, Moneycontrol, Chittorgarh, Upstox, Firstock, Kotak Securities